SEC Form 3 · accession 0002147277-26-000001
Scribe Therapeutics, Inc. · SCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brett Staahl
10% Owner
Period of report
Jul 23, 2026
Accepted (ET)
Jul 23, 2026 · 9:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001853921
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 524,336 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.08 | holding | — | — | — | — | Jun 7, 2030 | Common Stock | 2,462 | — | D |
| Stock Option (Right to Buy)F1 | $6.40 | holding | — | — | — | — | Aug 5, 2031 | Common Stock | 17,798 | — | D |
| Stock Option (Right to Buy)F1 | $19.13 | holding | — | — | — | — | Mar 12, 2036 | Common Stock | 4,755 | — | D |
| Stock Option (Right to Buy)F2 | $6.40 | holding | — | — | — | — | Mar 20, 2035 | Common Stock | 1,688 | — | D |
Explanation of responses
- F1The option is fully vested.
- F2The options vested as to 25% of the award on January 1, 2026, and the remaining 75% of the option will vest in equal monthly installments thereafter until such time as the options are 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.